Osiris Therapeutics, Inc. (OSIR)
A stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas.
Recs
minifesto
(< 20)
Submitted: 10/27/2009 2:24:59 PM :
Start Price:
$6.49
OSIR Score:
-0.85
Stem cell company with partnership with Genzyme. Market value $220 million with cash $130 million. Percieved failure lead product trial tanked stock.
Recs
riegonla
(60.86)
Submitted: 10/15/2009 1:43:04 AM :
Start Price:
$6.93
OSIR Score:
-5.34
14 US$ 1 Nov 2009
Recs
davbeirney
(< 20)
Submitted: 10/3/2009 7:09:27 PM :
Start Price:
$6.50
OSIR Score:
-4.51
There could be a potential merger with Genzyme. OSIR share price is attractive.
Recs
08PortfolioModel
(< 20)
Submitted: 9/18/2009 9:43:45 AM :
Start Price:
$7.54
OSIR Score:
-14.54
Current 7.71, Sept 18 09. Limit 7.55
Recs
Jmachine
(< 20)
Submitted: 9/14/2009 1:08:14 PM :
Start Price:
$7.87
OSIR Score:
-21.24
I say it's time to get in on this stock.
Recs
Broken196
(< 20)
Submitted: 9/9/2009 11:32:25 AM :
Start Price:
$7.72
OSIR Score:
+20.37
So much money lost on their failed drug.
Recs
kkconway
(90.20)
Submitted: 9/8/2009 3:40:13 PM :
Start Price:
$7.93
OSIR Score:
-23.41
Buy low, sell high. That's the theory, anyway. No research, just picking up after the 34% drop on bad news and hoping it gets better. I also sold puts in real portfolio, which will do offer a "fear and dread" premium, and a further cushion of safety in this volatile stock.
Recs
TMFmrquakeroats
(87.30)
Submitted: 9/8/2009 10:33:57 AM :
Start Price:
$12.64
OSIR Score:
+56.90
Rated one star.
Recs
sfmain
(< 20)
Submitted: 9/2/2009 9:41:53 AM :
Start Price:
$14.46
OSIR Score:
-64.39
super option yields and a firm 10.00 bottom
Recs
DTMINC
(< 20)
Submitted: 8/26/2009 2:16:54 PM :
Start Price:
$14.43
OSIR Score:
-60.95
New approval for phase III drug next week.
Recs
Brian7992
(< 20)
Submitted: 8/20/2009 7:40:30 AM :
Start Price:
$11.70
OSIR Score:
-53.50
Best Bio Bets
Recs
SteveTheBluesman
(74.38)
Submitted: 3/16/2009 9:46:58 AM :
Start Price:
$18.05
OSIR Score:
-108.56
The only stem company that makes money. Huge deal with Genzyme. They are ready to double.
Recs
SapphireSeas
(80.33)
Submitted: 3/8/2009 11:33:07 PM :
Start Price:
$18.75
OSIR Score:
-128.79
Reversal of 2001 Executive Order banning most forms of stem cell research will greatly assist OSIR long-term prospects:
http://www.forbes.com/feeds/ap/2009/03/06/ap6138011.html
Recs
marc64
(97.69)
Submitted: 2/27/2009 1:40:57 PM :
Start Price:
$17.84
OSIR Score:
-112.09
I would call this a speculative pick.
Either stem cell research has promise, or it does not. I'm betting that if stem cell-based therapy is developed carefully, the technology will eventually prove to have immense medical benefits. Not insignificantly, the new president has indicated support for this industry, and time is on this industry's side..
A lot of the recent political debate around embryo research has frightened off investors who are cautious about a political fallout. But, OSIR uses adult stem cells, and its basic competences in the science has given them a decent shot at being the first out of the gate to prove a safe, valuable adult stem cell therapy, covering diseases with huge numbers of sufferers, representing a huge potential market.
If OSIR succeeds, they will become a player in a frontier, high-tech medical niche.
Recs
supernaut2009
(< 20)
Submitted: 2/18/2009 11:34:10 PM :
Start Price:
$20.00
OSIR Score:
-106.62
With the Democrats in, this industry will receive a boost. I was "foolish" enough to sell this stock after a quick bounce shortly after its IPO. I am still a bit timid with this sector and its corresponding volatility...
Recs
JD2840
(< 20)
Submitted: 1/23/2009 2:12:15 PM :
Start Price:
$19.92
OSIR Score:
-100.54
Phase II data was exceptional.
This 'drug' (really cells) are the last in a line of options for patients dying of GVHD. If you don't know what GVHD is, you shouldn't rate this stock. The safety data thus far are exceptional, and if they have a little efficacy (and it looks like they have a lot), this will be a
This will be approved, and the use of the drug expanded rapidly.
At 15K per treatment (my numbers), they need a base of about 3500 patients to be a 500 million revenue.. should value at 5 bill or a 10 bagger...
Good luck
Recs
cyborsurfer
(< 20)
Submitted: 11/4/2008 7:34:22 PM :
Start Price:
$17.03
OSIR Score:
-74.48
Stock that has beat the S&P 500 most of 2008 and insiders own more than 10 percent of the stock.
Recs
Aarin7
(88.76)
Submitted: 7/31/2008 1:01:02 PM :
Start Price:
$16.00
OSIR Score:
+47.28
At $16, this stock is over priced. It has a lot of future potential but has very little profits to speak of. Their trials in adult stem research have shown major break troughs but are expensive. This stock should bloom with a more liberal president in office. In the short term, the stock is a $12-13 stock. In the long term, this stock will eventual explode IF they do not use all of their capital before FDA approval.
Recs
riskybus
(< 20)
Submitted: 7/8/2008 12:14:29 AM :
Start Price:
$14.05
OSIR Score:
-43.41
"Osiris was the God who made the seeds ripe for the harvesting, and also could raise those from the dead."
Recs
vladdfool
(88.49)
Submitted: 5/28/2008 11:07:16 PM :
Start Price:
$13.03
OSIR Score:
+31.00
Stem cell space still extremely risky with little hope for improvement over the next few years. Having worked with these cell lines, I can only say, it takes YEARS to get any positive experimental data worth anything, much less FDA approval and market acceptance. Hate to crap on my biotech bretheren, but this company loses lots and lots of money, and will continue to do so for quite some time to come...
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 41 1 2 3 Next »